The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Masimo (MASI Quick QuoteMASI - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Masimo is one of 817 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MASI is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for MASI's full-year earnings has moved 0.61% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, MASI has moved about 36.51% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.76%. This shows that Masimo is outperforming its peers so far this year.

To break things down more, MASI belongs to the Medical - Instruments industry, a group that includes 92 individual companies and currently sits at #91 in the Zacks Industry Rank. This group has gained an average of 14.93% so far this year, so MASI is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to MASI as it looks to continue its solid performance.